Literature DB >> 1314781

Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth?

O Nilsson1, B Wängberg, E Theodorsson, A Skottner, H Ahlman.   

Abstract

The presence of IGF-I and IGF-I receptors in human midgut carcinoid tumours has been investigated. Using immunocytochemistry, IGF-I-positive tumour cells were demonstrated in 11/11 tumour cases studied. Labelling of consecutive sections with antibodies against IGF-I and proliferating cell nuclear antigen (PCNA)/cyclin demonstrated a co-distribution of the 2 antigens in carcinoid tumours. Extracts of tumour tissues were subjected to radioimmunoassay and shown to contain significant amounts of IGF-I. Reverse-phase HPLC of tumour extracts demonstrated a major IGF-I-immunoreactive component eluting in the position of rhIGF-I, but also 2 other more hydrophobic forms. Conditioned serum-free media from primary cultures of carcinoid tumors contained detectable amounts of IGF-I, indicating a spontaneous release of IGF-I from tumour cells into the culture medium. Levels of IGF-I in media were reduced (19%) after incubation of cultures with a somatostatin analogue for 4 days. IGF-I receptors were observed on tumour cells in 4/10 tumours by immunocytochemistry. Tumour cells with immunoreactive IGF-I receptors could be stimulated to enhanced growth, measured as an increase in DNA contents, by exogenous administration of IGF-I every 3-4 days for 2 weeks. The results show that cultured human midgut carcinoid tumours secrete IGF-I and that some of the tumours also have IGF-I receptors. We therefore suggest that IGF-I may act as an autocrine or paracrine regulator of carcinoid tumour-cell growth.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314781     DOI: 10.1002/ijc.2910510206

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 2.  Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Mark Kidd; Irvin Modlin; Kjell Öberg
Journal:  Nat Rev Clin Oncol       Date:  2016-06-07       Impact factor: 66.675

3.  A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake.

Authors:  L Kölby; P Bernhardt; H Ahlman; B Wängberg; V Johanson; A Wigander; E Forssell-Aronsson; S Karlsson; B Ahrén; G Stenman; O Nilsson
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Serotonin and the 5-HT7 receptor: the link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors.

Authors:  Bernhard Svejda; Mark Kidd; Andrew Timberlake; Kathy Harry; Alexander Kazberouk; Simon Schimmack; Ben Lawrence; Roswitha Pfragner; Irvin M Modlin
Journal:  Cancer Sci       Date:  2013-05-24       Impact factor: 6.716

Review 5.  Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer.

Authors:  Ramon Salazar; Diane Reidy-Lagunes; James Yao
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

6.  Successful treatment of refractory midgut bleeding with ocreotide and corticosteroids in a dialysis patient with suspected sarcoidosis.

Authors:  Nestor Velasco; Toufeeq Imtiaz; Amir Ali Shah; Anastasios Koulaouzidis
Journal:  BMJ Case Rep       Date:  2016-07-14

Review 7.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

Review 8.  Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.

Authors:  Rossana Berardi; Francesca Morgese; Mariangela Torniai; Agnese Savini; Stefano Partelli; Silvia Rinaldi; Miriam Caramanti; Consuelo Ferrini; Massimo Falconi; Stefano Cascinu
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

Review 9.  Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms.

Authors:  Namrata Vijayvergia; Arvind Dasari
Journal:  Curr Treat Options Oncol       Date:  2020-10-07

10.  An analysis of trends and growth factor receptor expression of GI carcinoid tumors.

Authors:  Kanika A Bowen; Scott R Silva; Jessica N Johnson; Hung Q Doan; Lindsey N Jackson; Pat Gulhati; Suimin Qiu; Taylor S Riall; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2009-07-07       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.